Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,458 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Radiation Oncology Clear all

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: Chemotherapy, Lattice Radiotherapy (LRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Cancer
Interventions: Radiation, Paclitaxel, Cisplatin, 5-Fluorouracil; Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions: bevacizumab, fluorouracil, external beam radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis; Biological · Drug · Radiation + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Solid Cancer, Metastatic Spinal Lesions
Interventions: Dynamic contrast enhancement MRI; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Solid Tumors of Metastatic Disease
Interventions: Radiation Therapy, Systemic Therapy; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Muscle-invasive Urothelial Cancer of the Bladder
Interventions: Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine, External Beam Radiation Therapy; Biological · Procedure · Drug + 1 more
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 5
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more

Conditions: BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Interventions: Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib; Drug · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Duarte, California • Columbus, Ohio • Houston, Texas

Conditions: ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Pembrolizumab, Radiation Therapy; Biological · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Squamous Cell Carcinoma of the Oropharynx
Interventions: Radiation Therapy; Radiation
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Miami, Florida • Charlottesville, Virginia • Norfolk, Virginia + 1 more

Conditions: Brain Neoplasms, Malignant, Brain Neoplasms, Benign, Malignant Meningioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions: Pioglitazone; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
Interventions: octreotide acetate, yttrium Y 90 resin microspheres; Drug · Radiation
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms, Cancer of the Head
Interventions: erlotinib + celecoxib; Drug
Lead sponsor: Johnny Kao; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer Stage II, Breast Cancer Stage III
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
Interventions: BMX-001, Radiation Therapy, Temozolomide; Drug · Radiation
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 6 more

Conditions: Metastatic Cancer, Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Tumor, Metastatic Tumor of Bone, Metastatic Tumor to the Spine, Spine Metastases, Metastasis
Interventions: SBRT to the spine; Radiation
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Soft Tissue Sarcoma
Interventions: Conventional Fractionated, Hypofractionated; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
Interventions: Maintenance Radiotherapy; Radiation
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anal Cancer
Interventions: Pembrolizumab, Paclitaxel, Carboplatin, Radiation; Drug · Radiation
Lead sponsor: Dustin Deming; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Lattice Extreme Ablative Dose Radiation Therapy, Standard IMRT; Radiation
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: DPX-Survivac, Letrozole 2.5mg, Cyclophosphamide 50mg, XRT 10Gy x2; Biological · Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lung Neoplasm
Interventions: Stereotactic Radiotherapy, Anatomic Pulmonary Resection; Radiation · Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2034
U.S. locations: 17
States / cities: Long Beach, California • West Los Angeles, California • Bay Pines, Florida + 14 more

Conditions: Cancer Head Neck, Cancer, Head, Cancer Neck
Interventions: Machine Learning Assisted Radiation (MLAP) RapidPlan, Radiation Therapy Standard of Care (SOC); Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 3 more

Conditions: Endometrial Cancer
Interventions: Carboplatin and Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Marywood, Illinois

Conditions: Carcinoma, Hepatocellular
Interventions: Stereotactic Body Radiation; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma

Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

Definitive Radiation for High-Risk Spine Metastases

Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

Dose Escalation Study for Primary Hepatocellular Carcinoma